MANF

AcronymDefinition
MANFManifold
MANFMesencephalic Astrocyte-Derived Neurotrophic Factor (protein type)
MANFMake a Noise Foundation (Nashville, TN)
References in periodicals archive ?
MANF is in preclinical development for the treatment of orphan ophthalmological disorders, glaucoma and Parkinson's disease.
Positive Preclinical Data For Neurotrophic factor In Parkinson's Disease
Biotechnology company Amarantus Bioscience Holdings (Other OTC:AMBS) reported on Friday the receipt of the Chinese patent entitled "Neurodegenerative Disorders" covering the use of MANF for the treatment of Parkinson's disease and other neurodegenerative conditions.
Amarantus Bioscience Holdings awarded Chinese patent for MANF for the treatment of Parkinson's disease and other neurodegenerative conditions
MANF is a naturally-occurring protein that reduces and prevents apoptosis (programmed cell death) in response to injury or disease.
Amarantus, Catalent ink cGMP mfg. pact
En el grupo II el 80% de los MANF no presentaron remanente o tenian reseccion mayor al 75% (GI) versus el 64% en el grupo I, aunque esta diferencia no fue estadisticamente significativa.
Analisis y seguimiento en 50 cirugias trans-esfenoidales de la region sellar
MANF is released from glial cells in the midbrain and is a member of the same growth factor family as CDNF.
Novel therapeutic target for Parkinson's disease identified
Therefore, TECH, MANF and IND became one of few global players in a highly specialized product.
Explosive international growth and problems of success amongst small to medium-sized firms
According to the company, MANF is a naturally-occurring protein that reduces and prevents apoptosis (programmed cell death) in response to injury or disease.
Amarantus passes US FDA's orphan drug designation for MANF for retinal artery occlusion
13/305,025, will provide additional intellectual property protection for MANF (mesencephalic-astrocyte-derived neurotrophic factor) protein therapy and cell therapy.
Amarantus wins USPTO's Notice of Allowance for patent application covering proprietary compositions of matter and methods for MANF
The Opposition Division held that Hermo Phrama's arguments did not prejudice the maintenance of the patent as originally granted, with broad claims covering MANF and its derivatives.
RBCC Target Amarantus Wins MANF Patent Challenge in Europe
According to the company, it owns composition of matter patents and various composition and method of use patent applications for MANF and derivative sequences for protein therapeutic, gene therapy and certain cell therapy applications worldwide.
Amarantus announces exercise of option to license intellectual property from University of Miami Bascom Palmer Eye Institute for retinal disorders
Next up will be MANF, the groundbreaking new therapeutic protein that Amarantus is developing to treat Parkinson's disease and traumatic brain injuries.
RBCC Issues Shareholder Letter Celebrating Promising 2013
M2 EQUITYBITES-June 23, 2014-Amarantus partners with Washington University School of MedicineJack to evaluate the efficacy of MANF to treat Wolfram disease
Amarantus partners with Washington University School of MedicineJack to evaluate the efficacy of MANF to treat Wolfram disease
Acronyms browser ?
Full browser ?